Liposuction composition and preparation method therefor

Abstract

A composition of the present invention relates to a liposuction composition comprising: a basic solution containing NaCl; an anesthetic; and albumin. The composition of the present invention has the effect of improving the extraction yield and cell viability of adipose stem cells. In particular, stem cells present in adipose tissue can be efficiently isolated using the composition of the present invention. Since fat in the body can be effectively and safely aspirated, the present invention has high industrial applicability.

Description

Composition for liposuction and method for preparing the same

[0001] The present invention relates to a composition for liposuction containing albumin and a method for producing the same.

[0002] Liposuction is a surgical procedure that removes and corrects abnormally accumulated subcutaneous fat in the human body. It can easily remove accumulated fat in the body without long-term exercise or extreme dieting, and can provide health promotion and body improvement effects by reducing body fat and weight.

[0003] Liposuction uses a tumescent solution. This solution inflates fat cells, facilitating their effective removal. Fat cells are tightly tangled, and when injected, the tumescent solution penetrates them, causing them to swell. Then, a cannula is inserted to stimulate the fat cells, causing them to burst, making them easier to suction.

[0004] A tumescent solution is a solution containing a base solution (usually saline), a local anesthetic, a vasoconstrictor, and a pH adjuster. The local anesthetic is typically lidocaine, the vasoconstrictor is epinephrine, and the pH adjuster is Bivon (sodium bicarbonate). The base solution (solvent) makes up the largest proportion of the tumescent solution and functions to swell fat cells, allowing them to be easily ruptured and suctioned by a cannula. The local anesthetic numbs the surgical site, allowing for simultaneous local anesthesia and liposuction. The vasoconstrictor constricts blood vessels to reduce bleeding. The pH adjuster neutralizes the pH of the tumescent solution, which has become acidic due to lidocaine and epinephrine.

[0005] In this way, tumescent solution plays various roles in liposuction, such as facilitating the removal of fat cells, anesthetizing, reducing bleeding, and increasing the stability of anesthesia.

[0006] Meanwhile, adipose stem cells (ADCs) are stem cells isolated from the body's fat cells and possess the ability to differentiate into various cell types. Recently, the potential utility of ADCs has been highlighted, and research into their application is underway. This research requires not only highly efficient extraction of ADCs from adipose tissue, but also the maintenance of their stability.

[0007] Accordingly, the inventors of the present invention have endeavored to develop a composition for liposuction that can not only efficiently suck fat from human tissue but also effectively separate stem cells from separated adipose tissue, and as a result, they have confirmed that the composition for liposuction containing albumin according to the present invention not only achieves the above-mentioned purpose but also improves aftereffects (e.g., lumps and bruises) that occur during liposuction, thereby completing the present invention.

[0008] One aspect of the present invention is to provide a composition for liposuction.

[0009] Another aspect of the present invention provides a method for preparing a composition for liposuction.

[0010] According to embodiments of the present invention, the liposuction composition comprising albumin of the present invention can reduce damage to adipose stem cells and tissues aspirated. Furthermore, when liposuction is performed using this liposuction composition, adipose stem cells can be isolated from adipose tissue with high efficiency. Therefore, the use of this liposuction composition is expected to have significant commercial potential, as it can increase the utilization of adipose stem cells in conjunction with liposuction.

[0011] Figure 1 is a diagram showing the yield of adipose stem cells obtained from each adipose tissue after obtaining adipose tissue using a tumescent solution with albumin added to a basic solution of 0.45% saline solution, 0.9% saline solution, and Hartmann's solution, and a tumescent solution without albumin added.

[0012] Figure 2 is a diagram showing the survival rate of each adipose stem cell extracted with the above-described tumescent solution.

[0013] Figure 3 is a drawing showing the results of evaluating the degree of lumping as a post-symptom after liposuction using saline alone, saline with albumin added, and Hartmann's solution with albumin added.

[0014] Figure 4 is a drawing showing the results of evaluating the degree of bruising as a post-symptom after liposuction using saline solution alone, 0.45% saline solution with added albumin, and Hartmann's solution with added albumin.

[0015] One aspect of the present invention provides a composition for liposuction. The composition for liposuction may include a base solution, an anesthetic, and albumin.

[0016] As used herein, the term "albumin" refers to a protein that constitutes the basic substance of cells. It plays a crucial role in maintaining osmotic pressure between blood vessels and tissues by retaining body fluid within the blood vessels. Serum albumin accounts for 50-70% of total serum protein. When albumin concentration decreases, body fluid leaks out of the blood vessels, reducing blood volume and lowering blood pressure. This can lead to symptoms such as dizziness, edema, and ascites.

[0017] In one specific example, the albumin may be human serum albumin, recombinant albumin, or bovine serum albumin. Preferably, the albumin may be human serum albumin. In this case, albumin may exhibit antioxidant or anti-inflammatory effects under normal or oxidative stress conditions. Furthermore, it may form a reversible complex with an anesthetic agent, inducing gradual release of the anesthetic agent, thereby prolonging the anesthetic effect and enhancing adipose stem cell and cell survival.

[0018] As used herein, the term "stromal vascular fraction (SVF)" refers to a mixture of cells obtained from body adipose tissue. When the stromal vascular fraction is centrifuged, a cell layer containing various cells, such as fibroblasts, immune cells, microvascular endothelial cells, muscle cells, and preadipocytes, is precipitated, including adipose stem cells.

[0019] As used herein, the term "base solution" refers to an aqueous solution containing NaCl. Specifically, the base solution may be an aqueous solution of a salt containing sodium cations and chloride anions.

[0020] In one specific example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may further comprise a salt composed of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, dextrose, or a combination thereof.

[0021] For example, the aqueous solution of a salt containing a sodium cation and a chloride anion may contain one of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, or dextrose. Specifically, the aqueous solution may contain a potassium cation. The aqueous solution may contain a calcium cation. The aqueous solution may contain a magnesium cation. The aqueous solution may contain a lactate anion. The aqueous solution may contain dextrose.

[0022] For example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may comprise two components selected from the group consisting of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, and dextrose. Specifically, the aqueous solution may comprise a potassium cation and a calcium cation. The aqueous solution may comprise a potassium cation and a magnesium cation. The aqueous solution may comprise a potassium cation and a lactate anion. The aqueous solution may comprise a potassium cation and dextrose. The aqueous solution may comprise a calcium cation and a magnesium cation. The aqueous solution may comprise a calcium cation and a lactate anion. The aqueous solution may comprise a calcium cation and dextrose. The aqueous solution may comprise a magnesium cation and a lactate anion. The aqueous solution may comprise a magnesium cation and dextrose. The aqueous solution may comprise a lactate anion and dextrose.

[0023] For example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may comprise three components selected from the group consisting of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, and dextrose. Specifically, the aqueous solution may comprise potassium cations, calcium cations, and magnesium cations. The aqueous solution may comprise potassium cations, calcium cations, and lactate anions. The aqueous solution may comprise potassium cations, calcium cations, and dextrose. The aqueous solution may comprise potassium cations, magnesium cations, and lactate anions. The aqueous solution may comprise potassium cations, magnesium cations, and dextrose. The aqueous solution may comprise potassium cations, lactate anions, and dextrose. The aqueous solution may comprise calcium cations, magnesium cations, and lactate anions. The aqueous solution may comprise calcium cations, magnesium cations, and dextrose. The aqueous solution may contain calcium cations, lactate anions, and dextrose. The aqueous solution may contain magnesium cations, lactate anions, and dextrose.

[0024] For example, the aqueous solution of a salt containing the sodium cation and the chloride anion may contain four components selected from the group consisting of potassium cation, calcium cation, magnesium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain potassium cation, calcium cation, magnesium cation, and lactate anion. Specifically, the aqueous solution may contain potassium cation, calcium cation, magnesium cation, and dextrose. Specifically, the aqueous solution may contain potassium cation, calcium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain potassium cation, magnesium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain calcium cation, magnesium cation, lactate anion, and dextrose.

[0025] For example, the aqueous solution of a salt preferably comprising a sodium cation and a chloride anion may include potassium cation, calcium cation, magnesium cation, lactate anion and dextrose.

[0026] In one specific example, the base solution may be Hartman's solution, Hartman-Dex, saline, 1 / 2 saline, or 1 / 4 saline. Preferably, the base solution may be Hartman's solution. In this case, the burning sensation upon injection can be reduced, and lactate, which is converted to bicarbonate in the body, helps maintain the body's pH, thereby preventing metabolic acidosis. In addition, lactate can improve adipose stem cells and cell viability, and can alleviate inflammation and promote recovery of cells and tissues in the body.

[0027] As used herein, the term "Hartmann's solution" refers to an intravenous solution containing sodium chloride (6.0 g / L NaCl), potassium chloride (0.4 g / L KCl), calcium chloride dihydrate (0.27 g / L CaCl2·2H2O), and sodium lactate (3.1 g / L C3H5NaO3), adjusted to concentrations similar to those of body fluids in the human body. Hartmann's solution is also called Ringer's lactate or Ringer's solution.

[0028] As used herein, the term "Hartmandex" refers to glucose (50 g / L C6H) adjusted to a concentration similar to that of human body fluids. 12 O6, dextrose), sodium chloride (6.0 g / L NaCl), potassium chloride (0.3 g / L KCl), calcium chloride dihydrate (0.2 g / L CaCl2·2H2O), and sodium lactate (3.1 g / L C3H5NaO3).

[0029] The term "saline solution" as used herein refers to a sodium chloride (NaCl) solution whose concentration is adjusted to be similar to the concentration of body fluids of the human body. For example, the saline solution may be normal saline solution (0.9% NaCl), 1 / 2 saline solution (0.45% NaCl), or 1 / 4 saline solution (0.225% NaCl) by varying the sodium chloride concentration.

[0030] In one specific embodiment, the pH of the base solution may be from about 5.0 to about 7.0. Preferably, the pH of the base solution may be from about 5.0 to about 6.9, from about 5.0 to about 6.8, from about 5.3 to about 7.0, from about 5.3 to about 6.9, from about 5.3 to about 6.8, from about 5.5 to about 7.0, from about 5.5 to about 6.9, from about 5.5 to about 6.8, from about 5.6 to about 7.0, from about 5.6 to about 6.9, from about 5.6 to about 6.8, from about 5.8 to about 7.0, from about 5.8 to about 6.9, or from about 5.8 to about 6.8.

[0031] As used herein, the term "anesthetic" means a compound that temporarily blocks pain or causes loss of sensation by inhibiting the transmission of nerve signals.

[0032] In one specific example, the anesthetic may include any one selected from the group consisting of lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, etidocaine, ropivacaine, articaine, marcaine, polocaine, xylocaine, novocaine, procaine, carbocaine, and cinchocaine. Preferably, the anesthetic may be lidocaine. In this case, it reduces pain during and after surgery through anesthesia of a local area of ​​the body, and reduces the risk of postoperative infection because it has anti-inflammatory and antiviral properties.

[0033] In one specific example, the weight of the albumin may be from about 0.1 wt% to about 10 wt% based on the total weight of the composition. Preferably, the weight of the albumin may be from about 0.1 wt% to about 8 wt%, from about 0.1 wt% to about 5 wt%, from about 0.1 wt% to about 3 wt%, from about 0.3 wt% to about 10 wt%, from about 0.3 wt% to about 8 wt%, from about 0.3 wt% to about 5 wt%, from about 0.3 wt% to about 3 wt%, from about 0.5 wt% to about 10 wt%, from about 0.5 wt% to about 8 wt%, from about 0.5 wt% to about 5 wt%, from about 0.5 wt% to about 3 wt%, from about 0.7 wt% to about 10 wt%, from about 0.7 wt% to about 8 wt%, from about 0.7 wt% to about 5 wt%, or from about 0.7 wt% to about 3 wt% based on the total weight of the composition.

[0034] In one specific example, the weight of the anesthetic may be from about 0.05 wt% to about 20 wt% based on the total weight of the composition. Preferably, the weight of the anesthetic is from about 0.05 wt% to about 10 wt%, from about 0.05 wt% to about 5 wt%, from about 0.05 wt% to about 3 wt%, from about 0.1 wt% to about 20 wt%, from about 0.1 wt% to about 10 wt%, from about 0.1 wt% to about 5 wt%, from about 0.1 wt% to about 3 wt%, from about 0.3 wt% to about 20 wt%, from about 0.3 wt% to about 10 wt%, from about 0.3 wt% to about 5 wt%, from about 0.3 wt% to about 3 wt%, from about 0.5 wt% to about 20 wt%, from about 0.5 wt% to about 10 wt%, from about 0.5 wt% to about 5 wt%, from about 0.5 wt% to about 3 wt%, from about 0.7 wt% to about It can be 20 wt%, about 0.7 wt% to about 10 wt%, about 0.7 wt% to about 5 wt%, or about 0.7 wt% to about 3 wt%.

[0035] In one specific example, the albumin may be present in a weight ratio of about 1:0.05 to about 1:10 relative to the anesthetic. Preferably, the albumin may be present in a weight ratio of about 1:0.05 to about 1:8, about 1:0.05 to about 1:5, about 1:0.05 to about 1:3, about 1:0.1 to about 1:10, about 1:0.1 to about 1:8, about 1:0.1 to about 1:5, about 1:0.1 to about 1:3, about 1:0.5 to about 1:10, about 1:0.5 to about 1:8, about 1:0.5 to about 1:5, about 1:0.5 to about 1:3, about 1:1 to about 1:10, about 1:1 to about 1:8, about 1:1 to about 1:5, or about 1:1 to about 1:3.

[0036] In one specific example, the liposuction composition may further comprise an adjuvant. The adjuvant may comprise at least one selected from the group consisting of a vasoconstrictor or a pH regulator.

[0037] As used herein, the term "adjuvant" means an ingredient added to a composition to enhance the effect of the composition or to increase the safety of the composition in the body.

[0038] In one specific example, the vasoconstrictor may include any one selected from the group consisting of epinephrine, norepinephrine, phenylephrine, EPI-sugacaine, and tropicamide. Preferably, the vasoconstrictor may be epinephrine. In this case, bleeding can be alleviated through vasoconstriction in the body, and the local anesthetic effect can be prolonged by delaying the blood absorption of the anesthetic.

[0039] In one specific example, the pH adjuster may be any one selected from the group consisting of Bivon (sodium bicarbonate), sodium citrate, sodium lactate, sodium dihydrogen phosphate, and disodium hydrogen phosphate. Preferably, the pH adjuster may be Bivon. In this case, the pH of the composition that has become acidic due to an anesthetic or an anesthetic and a vasoconstrictor can be neutralized, thereby alleviating pain in the body or increasing the anesthetic effect.

[0040] In one specific example, the liposuction composition may comprise about 0.1 wt% to about 10 wt% of the albumin, about 0.05 wt% to about 20 wt% of the anesthetic, about 0.01 wt% to about 20 wt% of the adjuvant, and the balance of the base solution. Preferably, the liposuction composition may independently comprise, for each component, about 0.1 wt% to about 8 wt%, about 0.1 wt% to about 5 wt%, about 0.1 wt% to about 3 wt%, about 0.3 wt% to about 10 wt%, about 0.3 wt% to about 8 wt%, about 0.3 wt% to about 5 wt%, about 0.3 wt% to about 3 wt%, about 0.5 wt% to about 10 wt%, about 0.5 wt% to about 8 wt%, about 0.5 wt% to about 5 wt%, about 0.5 wt% to about 3 wt%, about 0.7 wt% to about 10 wt%, about 0.7 wt% to about 8 wt%, about 0.7 wt% to about 5 wt%, or about 0.7 wt% to about 3 wt% of the albumin, and about 0.05 wt% to about 10 wt%, about 0.05 wt% to about 5 wt%, about 0.05 wt% to about 3 wt%, about 0.1 wt% to about 20 wt%, about 0.1 wt% to about 10 wt%, about 0.1 wt% to about 5 wt%, about 0.1 wt% to about 3 wt%, about 0.3 wt% to about 20 wt%, about 0.3 wt% to about 10 wt%, about 0.3 wt% to about 5 wt%, about 0.3 wt% to about 3 wt%, about 0.5 wt% to about 20 wt%, about 0.5 wt% to about 10 wt%, about 0.5 wt% to about 5 wt%, about 0.5 wt% to about 3 wt%, about 0.7 wt% to about 20 wt%, about 0.7 wt% to about 10 % by weight, about 0.7 wt % to about 5 wt %, or about 0.7 wt % to about 3 wt %, and the adjuvant may be comprised of about 0.It can comprise from about 0.1 wt% to about 10 wt%, from about 0.01 wt% to about 5 wt%, from about 0.01 wt% to about 3 wt%, from about 0.05 wt% to about 20 wt%, from about 0.05 wt% to about 10 wt%, from about 0.05 wt% to about 5 wt%, from about 0.05 wt% to about 3 wt%, from about 0.1 wt% to about 20 wt%, from about 0.1 wt% to about 10 wt%, from about 0.1 wt% to about 5 wt%, from about 0.1 wt% to about 3 wt%, from about 0.5 wt% to about 20 wt%, from about 0.5 wt% to about 10 wt%, from about 0.5 wt% to about 5 wt%, or from about 0.5 wt% to about 3 wt%, and can comprise the balance of the base solution.

[0041] In one specific example, the composition for liposuction can be used to extract adipose stem cells.

[0042] When the liposuction composition containing the above-described base solution is used, the adipose stem cell extraction yield and cell viability can be significantly increased. When the liposuction composition containing the above-described albumin is used, the adipose stem cell extraction yield and cell viability can be significantly increased.

[0043] Another aspect of the present invention provides a method for preparing a composition for liposuction. The method for preparing the composition for liposuction may include the steps of preparing a base solution; and adding an anesthetic and albumin to the base solution.

[0044] In one specific example, the base solution may be an aqueous solution of a salt containing a sodium cation and a chloride anion.

[0045] In one specific example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may further comprise a salt composed of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, dextrose, or a combination thereof.

[0046] For example, the aqueous solution of a salt containing a sodium cation and a chloride anion may contain one of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, or dextrose. Specifically, the aqueous solution may contain a potassium cation. The aqueous solution may contain a calcium cation. The aqueous solution may contain a magnesium cation. The aqueous solution may contain a lactate anion. The aqueous solution may contain dextrose.

[0047] For example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may comprise two components selected from the group consisting of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, and dextrose. Specifically, the aqueous solution may comprise a potassium cation and a calcium cation. The aqueous solution may comprise a potassium cation and a magnesium cation. The aqueous solution may comprise a potassium cation and a lactate anion. The aqueous solution may comprise a potassium cation and dextrose. The aqueous solution may comprise a calcium cation and a magnesium cation. The aqueous solution may comprise a calcium cation and a lactate anion. The aqueous solution may comprise a calcium cation and dextrose. The aqueous solution may comprise a magnesium cation and a lactate anion. The aqueous solution may comprise a magnesium cation and dextrose. The aqueous solution may comprise a lactate anion and dextrose.

[0048] For example, the aqueous solution of a salt comprising a sodium cation and a chloride anion may comprise three components selected from the group consisting of a potassium cation, a calcium cation, a magnesium cation, a lactate anion, and dextrose. Specifically, the aqueous solution may comprise potassium cations, calcium cations, and magnesium cations. The aqueous solution may comprise potassium cations, calcium cations, and lactate anions. The aqueous solution may comprise potassium cations, calcium cations, and dextrose. The aqueous solution may comprise potassium cations, magnesium cations, and lactate anions. The aqueous solution may comprise potassium cations, magnesium cations, and dextrose. The aqueous solution may comprise potassium cations, lactate anions, and dextrose. The aqueous solution may comprise calcium cations, magnesium cations, and lactate anions. The aqueous solution may comprise calcium cations, magnesium cations, and dextrose. The aqueous solution may contain calcium cations, lactate anions, and dextrose. The aqueous solution may contain magnesium cations, lactate anions, and dextrose.

[0049] For example, the aqueous solution of a salt containing the sodium cation and the chloride anion may contain four components selected from the group consisting of potassium cation, calcium cation, magnesium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain potassium cation, calcium cation, magnesium cation, and lactate anion. Specifically, the aqueous solution may contain potassium cation, calcium cation, magnesium cation, and dextrose. Specifically, the aqueous solution may contain potassium cation, calcium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain potassium cation, magnesium cation, lactate anion, and dextrose. Specifically, the aqueous solution may contain calcium cation, magnesium cation, lactate anion, and dextrose.

[0050] For example, the aqueous solution of a salt preferably comprising a sodium cation and a chloride anion may include potassium cation, calcium cation, magnesium cation, lactate anion and dextrose.

[0051] In one specific example, the anesthetic may include any one selected from the group consisting of lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, etidocaine, ropivacaine, articaine, marcaine, polocaine, xylocaine, novocaine, procaine, carbocaine, and cincocaine. Preferably, the anesthetic may be lidocaine.

[0052] In one specific example, the albumin may be human serum albumin, recombinant albumin, or bovine serum albumin. Preferably, the albumin may be human serum albumin.

[0053] In one specific example, the method for preparing the composition for liposuction may further include, after adding the anesthetic and albumin, a step of adding an adjuvant including at least one selected from the group consisting of a vasoconstrictor and a pH regulator.

[0054] In one specific embodiment, the vasoconstrictor may include any one selected from the group consisting of epinephrine, norepinephrine, phenylephrine, EPI-sugacaine, and tropicamide. Preferably, the vasoconstrictor may be epinephrine.

[0055] In one specific example, the pH adjuster may be any one selected from the group consisting of Bivon (sodium bicarbonate), sodium citrate, sodium lactate, sodium dihydrogen phosphate, and sodium dihydrogen phosphate. Preferably, the pH adjuster may be Bivon.

[0056] The following examples are provided for more detailed explanation. However, these examples are provided for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0057] Example 1. Preparation of tumescent solution

[0058] Tumescent solutions were prepared according to the compositions shown in Table 1 below. Specifically, normal saline (0.9% NaCl, isotonic solution), 1 / 2 saline (0.45% NaCl, stock solution), and Hartmann's solution (isotonic solution) were prepared as base solutions, and epinephrine, bivon (sodium bicarbonate), lidocaine, epinephrine, and human serum albumin (Green Cross or SK Plasma) were added to the base solutions to prepare compositions of examples and comparative examples.

[0059] Classification (Unit: wt%)Basic solution (content)Anesthetic (content)AdjuvantAlbumin (content)Vasoconstrictor (content)pH regulator (content)Example 1Normal saline (residual)Lidocaine (2%)Epinephrine (1%)Vibbon (2%)Human serum albumin (1%)Comparative example 1Normal saline (residual)Lidocaine (2%)Epinephrine (1%)Vibbon (2%)N / AExample 21 / 2 physiological saline (residual)Lidocaine (2%)Epinephrine (1%)Vibbon (2%)Human serum albumin (1%)Comparative example 21 / 2 physiological saline (residual)Lidocaine (2%)Epinephrine (1%)Vibbon (2%)N / AExample 3Hartmann solution (residual)Lidocaine (2%)Epinephrine (1%)Vibbon (2%)Human serum Albumin (1%) Comparative Example 3 Hartmann's solution (residual amount) Lidocaine (2%) Epinephrine (1%) Vivon (2%) N / A

[0060] Experimental Example 1. Evaluation of Adipose Stem Cell Extraction Yield

[0061] Experimental Example 1.1. Preparation of Experimental Solution

[0062] Hartmann's solution was heated in a 37°C water bath for 30 minutes. 8 mL of human serum albumin (20% albumin) was mixed with 160 mL of Hartmann's solution heated to 37°C to prepare Hartmann's solution containing 1% human serum albumin.

[0063] 71.4 mg of collagenase (Nordmark Pharma GmbH) was mixed with Hartmann's solution containing 1% human serum albumin. The solution was then heated in a water bath at 37°C to prepare the experimental solution.

[0064] Experimental Example 1.2. Pretreatment of Adipose Tissue

[0065] Human adipose tissue (50 mL) was placed in each of three conical tubes and centrifuged at 300 × g for 5 minutes. The upper layer of fat and the lower layer of solution were removed using a suction pump. The residue was washed with Hartmann's solution containing 1% human serum albumin, and the process of centrifugation at 300 × g for 5 minutes was repeated three times to purify the fat layer.

[0066] Experimental Example 1.3. Extraction of Adipose Stem Cells

[0067] After mixing the purified lipid layer and the experimental solution of Experimental Example 1.1, the mixture was reacted at 37°C for 1.5 hours using a rotary mixer at 30 rpm. Afterwards, the reaction mixture was centrifuged at 300xg for 10 minutes to separate the cell layer.

[0068] 1X red blood cell lysis solution was prepared by mixing 10X red blood cell lysis buffer and sterile distilled water. The 1X red blood cell lysis solution was reacted at room temperature for 10 minutes to remove red blood cells, and the cells were washed with Hartmann's solution containing 1% human serum albumin. The residue was centrifuged at 300xg for 5 minutes to purify the cells. The cells were then filtered using a 70 μm cell strainer and centrifuged again at 300xg for 5 minutes to purify the cells. Finally, the cells were purified by centrifugation at 300xg for 5 minutes.

[0069] Experimental Example 1.4. Measurement of Adipose Stem Cell Extraction Yield According to the Type of Base Solution and the Presence or Absence of Albumin

[0070] Total cell count and viability were measured using an automatic cell counter (LUNA-FX7 cell counter, Logos Biosystems) and are shown in Table 2 below.

[0071] Adipose stem cell extraction yield (multiple difference) Adipose stem cell survival rate (%) Comparative example 11.0081.97 Example 11.8490.81 Comparative example 21.0176.25 Example 21.6380.62 Comparative example 31.4988.89 Example 32.0993.44

[0072] As a result of the experiment, the composition of Example 1 showed a 1.84-fold higher adipose stem cell extraction yield than the composition of Comparative Example 1, and the composition of Example 3 showed a 2.09-fold higher adipose stem cell extraction yield than the composition of Comparative Example 1. Figure 1 is a chart graphically illustrating the relative values ​​of the adipose stem cell extraction yields of the compositions of Comparative Example 1, Example 1, Comparative Example 2, Example 2, Comparative Example 3, and Example 3, which are the experimental results.

[0073] As a result, it was confirmed that adding albumin resulted in more efficient harvesting of adipose-derived stem cells. This demonstrates that albumin's cell membrane protective function consistently operates in various tumescent-based solutions (isotonic, hypotonic, and electrolyte-based solutions).

[0074] Experimental Example 1.5. Measurement of Adipose Stem Cell Viability According to the Type of Base Solution and the Presence or Absence of Albumin

[0075] The survival rate of adipose stem cells obtained using the experimental method used in Experimental Example 1.4 was measured.

[0076] As a result, it was confirmed that when 1% human serum albumin was added to all base solutions (0.45% saline, 0.9% saline, Hartmann's solution), the viability of adipose stem cells consistently increased compared to when albumin was not added. This demonstrates that the composition of the present invention not only secures a large number of adipose stem cells, but also has a compositional advantage of simultaneously maintaining cell viability and functional activity.

[0077] Experimental Example 2. Clinical Evaluation of Post-Liposuction Symptoms According to the Type of Base Solution and the Presence or Absence of Albumin

[0078] The subjects were administered tumescent solutions with or without albumin, as well as the type of base solution, to assess the severity of post-liposuction symptoms. Specifically, the severity of lumps and bruising was assessed as post-liposuction symptoms (Tables 3 to 5, Figures 3 and 4).

[0079] Number of participants in the comparison group: 1 week f / u completed 1 / 2 saline tumescent + 0.2% albumin 25 19 Hartman tumescent + 0.2% albumin 27 18 1 / 2 saline tumescent 25 25

[0080] Bruise grade: minimal; less than 10% of the treated area; mild; less than 20% of the treated area; moderate; less than 50% of the treated area; severe; more than 50% of the treated area

[0081] Grade of lump: Minimal; Less than 10% of the treatment area Mild; Less than 20% of the treatment area Moderate; Less than 50% of the treatment area Severe; More than 50% of the treatment area

[0082] As a result of analyzing the distribution differences between the three groups using the nonparametric statistical technique Kruskal-Wallis test, a statistically significant difference (P < 0.05) in the average ranks between the three groups was confirmed.

[0083] Compared to the basic tumescent solution (1 / 2 saline solution), the compositions with 0.2% albumin added (1 / 2 saline solution + albumin, Hartmann's solution + albumin) showed a lower average ranking of post-liposuction symptoms, indicating a tendency for symptom relief due to the addition of albumin (Table 6).

[0084] Group N Average Rank P-value Clump 1 / 2 Saline + albumin 1931.320.012 Hartman + albumin 1824.97 1 / 2 saline 2536.34 Total 62 Clump 1 / 2 Saline + albumin 1929.630.014 Hartman + albumin 1824.17 1 / 2 saline 2538.20 Total 62

[0085] In particular, when compared under conditions where albumin was added in the same amount, the tumescent composition using Hartmann's solution as a base solution showed a significantly better effect in improving clumping and bruising than the tumescent composition using 1 / 2 saline as a base solution (Figs. 3 and 4).

[0086] 1 / 2 Saline + albumin vs Hartman + albuminp = 0.3131 / 2 Saline + albumin vs 1 / 2 salineP = 0.126Hartman + albumin vs 1 / 2 salineP = 0.004

[0087] 1 / 2 Saline + albumin vs Hartman + albuminp = 0.3271 / 2 Saline + albumin vs 1 / 2 salineP = 0.075Hartman + albumin vs 1 / 2 salineP = 0.007

[0088] This trend is consistent with data on adipose-derived stem cell extraction yield and survival rate. Therefore, it was found that the Hartmann solution with albumin significantly improved not only adipose-derived stem cell extraction yield and survival rate, but also clinical sequelae.

Claims

1. A composition for liposuction comprising a base solution, an anesthetic and albumin.

2. In paragraph 1, A composition for liposuction, wherein the albumin comprises human serum albumin, recombinant albumin or bovine serum albumin.

3. In paragraph 1, A composition for liposuction, wherein the base solution comprises an aqueous solution of a salt containing sodium cations and chloride anions.

4. In paragraph 3, A composition for liposuction, wherein the base solution further comprises an aqueous solution of a salt composed of potassium cations, calcium cations, magnesium cations, lactate anions, dextrose or a combination thereof.

5. In paragraph 1, A composition for liposuction, wherein the base solution comprises Hartmann's solution, Hartmanndex, saline, 1 / 2 saline or 1 / 4 saline.

6. In paragraph 1, A composition for liposuction, wherein the pH of the above-mentioned basic solution is about 5.0 to about 7.

0.

7. In paragraph 1, A composition for liposuction, wherein the anesthetic comprises any one selected from the group consisting of lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, etidocaine, ropivacaine, articaine, marcaine, polocaine, xylocaine, novocaine, procaine, carbocaine, and cinchocaine.

8. In paragraph 1, A composition for liposuction, wherein the albumin comprises about 0.1% to about 10% of the total weight of the composition.

9. In paragraph 1, A composition for liposuction, wherein the anesthetic is contained in an amount of about 0.05% to about 20% based on the total weight of the composition.

10. In paragraph 1, A composition for liposuction, wherein the albumin is present in a weight ratio of about 1:0.05 to about 1:10 with respect to the anesthetic.

11. In paragraph 1, A composition for liposuction further comprising an adjuvant.

12. In paragraph 11, A composition for liposuction, wherein the adjuvant comprises at least one selected from the group consisting of a vasoconstrictor and a pH regulator.

13. In paragraph 12, A composition for liposuction, wherein the vasoconstrictor comprises any one selected from the group consisting of epinephrine, norepinephrine, phenylephrine, EPI-sugacaine, and tropicamide.

14. In paragraph 12, A composition for liposuction, wherein the pH adjusting agent is any one selected from the group consisting of Bivon (sodium bicarbonate), sodium citrate, sodium lactate, sodium dihydrogen phosphate, and sodium dihydrogen phosphate.

15. In paragraph 10, About 0.1% to about 10% by weight of the albumin; About 0.05 wt% to about 20 wt% of the anesthetic; About 0.01 wt% to about 20 wt% of the above auxiliary agent; and A composition for liposuction, comprising a residual amount of a base solution.

16. In paragraph 1, A composition for liposuction used for extracting adipose stem cells.

17. Step of preparing the base solution; and A method for preparing a composition for liposuction, comprising the step of adding an anesthetic and albumin to the above-mentioned basic solution.

18. In paragraph 17, A method for producing a composition for liposuction, wherein the base solution comprises an aqueous solution of a salt containing a sodium cation and a chloride anion.

19. In paragraph 18, A method for producing a composition for liposuction, wherein the base solution further comprises an aqueous solution of a salt composed of potassium cations, calcium cations, magnesium cations, lactate anions, dextrose or a combination thereof.

20. In paragraph 17, A method for producing a composition for liposuction, wherein the anesthetic comprises any one selected from the group consisting of lidocaine, tetracaine, mepivacaine, prilocaine, bupivacaine, etidocaine, ropivacaine, articaine, marcaine, polocaine, xylocaine, novocaine, procaine, carbocaine, and cincocaine.

21. In paragraph 17, A method for producing a composition for liposuction, wherein the albumin comprises human serum albumin, recombinant albumin or bovine serum albumin.

22. In paragraph 17, A method for preparing a composition for liposuction, further comprising the step of adding an adjuvant comprising at least one selected from the group consisting of a vasoconstrictor and a pH regulator after adding an anesthetic and albumin.

Images